New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung repair, and improved lung function LA JOLLA, CA, Jan. 08, 2026 (GLOBE NEWSWIRE) ...

Patients with SARD-ILD-PPF who continued nintedanib for 12 months or longer had better outcomes than those who discontinued therapy.

Proteomic mass spectrometry can identify key biomarkers in IPF, aiding in diagnosis and prognosis despite the disease's ...

Estimated YUTREPIA net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year 2025Received more than 2,800 unique patient prescriptions since launch in Jun ...

Estimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year ...

The Phase 2a trial enrolled 35 IPF patients randomized in a 2:1 ratio to receive either GRI-0621 or placebo once daily for 12 weeks. A sub-study examined immune cells in bronchoalveolar lavage fluid ...

In idiopathic pulmonary fibrosis, 12 months of pulmonary rehabilitation increased cerebral oxygenation during exercise, ...

Systemic therapy for sarcoidosis is reserved for organ-threatening disease, and laryngeal involvement necessitates treatment ...

Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2.4% decrease for the ...

Interim data from Phase 1 with single and multiple ascending doses show no safety signals and a generally favorable tolerability profile of ...

The gut bacteria B. adolescentis eased lung scarring in a pulmonary fibrosis mouse model, showing potential as a preventive ...

Labcorp is a global leader of innovative and comprehensive laboratory services. The company's Venture Fund invests in and supports early stage, private companies that are focused on improving health ...